Mobile Application for IBD Patients With Biologics

Overview

Monitoring of biologic treatment in patients with inflammatory bowel disease (IBD) is important given the increased risk of infections. In this study we aim to evaluate the use of a mobile application to guide IBD patients and facilitate the monitoring of biologic treatment.

Full Title of Study: “A Mobile Application Guiding Patients With Inflammatory Bowel Disease During Biologic Treatment”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Health Services Research
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 1, 2021

Detailed Description

Biologic treatment can induce and maintain remission in patients with inflammatory bowel disease (IBD). However, biologics are associated with increased risk of infections. Therefore, it is important to regularly monitor patients during the course of therapy. This process can be time consuming for patients as well as clinicians. Mobile applications, have the potential to guide patients and facilitate monitoring of biologic treatment. In this study we aim to evaluate the use of a mobile application to guide IBD patients during biologic treatment. Adult patients with diagnosis of IBD treated with biologics will be included. The mobile application with personalised content will give patients information about their treatment, reminders for example when blood tests and questionnaires to check for adverse events.

Interventions

  • Device: Personalised mobile application for IBD patients
    • Patients will use a mobile application for ±6months (exact period depends on interval of biologic treatment) with the following functionalities: Personal interactive timeline to prepare for biologic treatment with reminders for blood tests, a questionnaire to exclude contra-indications for biologic treatment (e.g. current infection) and a message from the gastroenterology nurse when blood tests results and the questionnaire have been checked. Only in case of abnormal results or answers patients will be contacted by telephone by their gastroenterology nurse, which is currently standard care. Information about the patients’ diagnosis and biologic treatment. General information on e.g. IBD treatment, vaccinations, frequently used medical terms, preparing for outpatient visits, what to do in case of disease symptoms. Patients will fill in a questionnaire to measure study outcomes at baseline and at the end of the study period.

Arms, Groups and Cohorts

  • Experimental: Personalised mobile application for IBD patients
    • This is a cohort study with a 1 arm intervention group, without a control group. Patients included in this study will be invited to use a mobile application. The content and functionalities of this application are described in the intervention section.

Clinical Trial Outcome Measures

Primary Measures

  • Patient satisfaction
    • Time Frame: 6 months
    • All patients will be asked to complete questions about satisfaction with the mobile application, the information in the app and the user-friendliness of the app. This will be measured with a 7-point likert scale after using the application for ± 6 months. We will also ask patients about their overall satisfaction of care before and after implementation of the application using a visual analogue scale (VAS) scale 0 – 10.
  • Actual use – frequency
    • Time Frame: 6 months
    • Use will be monitored with log data of the application. We will look at frequency of use of the application.
  • Adherence
    • Time Frame: 6 months
    • The adherence of patients to reminders will be evaluated by checking time of blood tests as recorded in the electronic medical record and log data from administered questionnaires.

Secondary Measures

  • Satisfaction of care providers
    • Time Frame: 6 months
    • After ± 6 months, health care professionals will be asked to fill in a questionnaire to measure their experiences with the application, experience with monitoring the questionnaire, satisfaction, organizational advantages/disadvantages for example time investment, efficiency of work processes. This will be measured with a 7-point likert scale after using the application for ± 6 months. We will also ask care providers about their overall satisfaction with the application using a VAS scale 0 – 10.
  • Overall satisfaction of care providers
    • Time Frame: 6 months
    • We will ask care providers about their overall satisfaction with the application using a VAS scale 0 – 10.
  • Number of outpatient visits
    • Time Frame: 6 months
    • The total number of outpatients visits in the six months before and after implementation of the application will be compared.
  • Number of telephone contacts
    • Time Frame: 6 months
    • The total number of telephone contacts in the six months before and after implementation of the application will be compared.
  • Disease and treatment knowledge
    • Time Frame: 6 months
    • The knowledge of disease and its treatment of patients before and after implementation of the application will be compared and assessed using a VAS Scale (scale 0 – 10).

Participating in This Clinical Trial

Inclusion Criteria

  • Diagnosis of inflammatory bowel disease – Treatment with infliximab or vedolizumab – Ability to read and understand Dutch language Exclusion Criteria:

  • Patients recently started with biologic treatment

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Rijnstate Hospital
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.